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Abstract 
 
 Muscle cells must anchor to their environment, the extracellular matrix (ECM), in 
order to function properly. Muscular dystrophy occurs when muscle cells cannot anchor 
to the ECM because specific protein complexes, such as the dystroglycan complex, are 
disrupted. Previously published studies have shown that overexpressing Paxillin can 
reduce dystrophy in dag1 deficient embryos. The aim of this study is to determine which 
domains of Paxillin are necessary to rescue dystrophy by overexpressing Paxillin with the 
LD2 or LD4 domains knocked out in dystrophic embryos. However, disruption of Dag1 
via the previous method stopped producing the muscular dystrophy phenotype, so ethanol 
(EtOH) treatment was used to induce dystrophy. It was determined that this is not a 
sufficient method of inducing dystrophy for this study. The EtOH treatment was 
inconsistent, and Paxillin overexpression was unable to rescue dystrophy in EtOH treated 
zebrafish. Furthermore, the dystrophy seen in EtOH treated embryos was much more 
severe than that seen in typical muscular dystrophy. Although this experiment could not 
be used to determine the necessity of the LD domains of Paxillin, it did give insight into 
the toxicity of EtOH. This information will be useful as we move on using different 
techniques.  
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Introduction 
 
 Cells are the building blocks of our body and it is critical to our survival that they 
function properly, but most cells cannot do this if they are not anchored to their 
environment (the extracellular matrix or ECM). This ECM is the substance that lies 
between cells and contains many proteins that act as a point of attachment for cells.[1] 
This requirement for attaching to the ECM is especially true of muscle cells, which 
function by continuously contracting and relaxing; exhibiting a force on their 
environment. Thus, muscle cells cannot function in voluntary movement of the body on 
their own and must have some component to anchor them.[2] This component is the 
myotendinous junction (MTJ), where muscles anchor to tendons. The MTJ is rich in 
extracellular matrix. During zebrafish early embryonic muscle development small 
precursor cells elongate to the MTJ and then bind to ECM proteins at the MTJ as an 
anchor.[3]  
 Two of the major types of macromolecules found within the ECM are the 
proteoglycans, a gel like substance that fills the interstitial space between the proteins, 
and the fibrous proteins, mostly collagens, elastins, fibronectins, and laminins.[4] Many of 
these adhesion proteins are found within a subunit of the ECM called the basement 
membrane. Of particular importance is laminin, which is a cross-shaped protein found 
within the basal lamina of the basement membrane. It is involved in binding the 
intracellular actin cytoskeleton of the muscle cell to the basement membrane of the MTJ. 
This attachment can either occur through laminin binding to transmembrane integrin 
proteins of the cell, or through laminin binding to the dystroglycan complex (DGC). 
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 The DGC is a transmembrane protein complex consisting of alpha and beta 
subunits. The intracellular β-dystroglycan subunit lies within the membrane and binds to 
a rod-shaped protein called dystrophin in the cytosol of the cell.[5] Dystrophin anchors β-
dystroglycan to actin within the cytoskeleton. The α-dystroglycan subunit binds to β-
dystroglycan within the membrane, but also has a region that lies outside of the 
membrane and links to laminin. The LG4-5 tail region of laminin binds to the highly 
glycosylated α-dystroglycan subunit while the alpha-1 LN at the top of laminin binds to 
type IV collagen in the BM.[6] 
  There are multiple pathologies that result from a disruption of this attachment. 
This is the case in many of the congenital muscular dystrophies (CMD) including 
Duchenne (DMD) and Becker muscular dystrophies, which have a mutation in 
dystrophin. These are x-linked recessive diseases that appear most frequently in young 
males.[7] The major symptom is muscle wasting, which can become so severe that it 
limits lung and cardiac function. Children are typically diagnosed between three and five 
years of age, and in the case of DMD generally have a short life expectancy of about 25 
years. Becker muscular dystrophy is caused by a different dystrophin allele, is milder, 
and occurs less frequently.[5] 
  In both variations of the disease the mutation on the X chromosome is for the 
intracellular protein dystrophin.[5] When this is altered or missing β-dystroglycan is 
unable to anchor to the actin cytoskeleton. With use, the muscle cell-BM attachment 
and/or the muscle membrane tear, and the muscle cells recoil and degenerate. This results 
in atrophy of the muscle that worsens over time, generally causing significant reduction 
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in muscle mass. The severity varies depending on the individual and on the type of 
dystrophy, but in many cases their life is severely impaired.  
 An excellent model for studying muscular dystrophies is the zebrafish. Zebrafish 
have external fertilization, which makes them ideal compared to other model organisms, 
such as mice, that gestate in utero. This form of reproduction allows us to view and 
manipulate early stages of development beginning at fertilization. Zebrafish also have 
translucent bodies, making visibility of muscle segmentation distinctly clear even under a 
simple dissecting microscope. Above all of this, the zebrafish share 70% of the same 
DNA as humans [8] and display the same phenotypes for congenital muscular dystrophies. 
This includes conserved sequences for dystrophin and dystroglycan across humans and 
zebrafish.  
 Recent studies have used zebrafish as a model to study the relationship between 
muscle cells and the MTJ as a way to treat dystrophy. The Henry lab has shown how 
activating the Nrk2b pathway can result in increased polymerization of laminin at the 
MTJ and improved muscle cell attachment. This involved supplementing exogenous 
NAD+ precursors to Dag1 morphants, which are embryos that lack dystroglycan and 
express symptoms of a type of muscular dystrophy known as dystroglycanopathy. This 
treatment was successful in improving both muscle health and motility [9]. Paxillin, which 
is a cell adhesion molecule found downstream of the NAD+ pathway, was also 
discovered to contribute to a reduction in muscle fiber detachments when the gene for it 
was overexpressed in Dag1 morphants. Dag1 morphant embryos showed improved 
muscle health as well as increased organization of laminin at the MTJ. Paxillin 
overexpression did not, however, rescue motility [9].  
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 This elicited some curiosity in how Paxillin is acting within the cell; specifically 
how it is contributing to laminin polymerization. This is the central question behind this 
research. Paxillin is a cell adhesion molecule that is believed to be involved in multiple 
signaling pathways. There are several domains within Paxillin, several of which act as 
docking sites for other proteins [10]. One such example is with the integrins, but it is 
unclear what the mechanisms are behind this relationship. The study done by Goody et al. 
displayed a correlation between increased Paxillin and increased polymerization and 
organization of laminin at the MTJ. Understanding the mechanisms behind this could 
potentially lead to new opportunities in treatment of muscular dystrophy.  
 One way to glean this information would be to look at each domain of Paxillin 
and determine which ones are contributing to its ability to ameliorate dystrophy. This 
could be done by overexpressing Paxillin with specific domains knocked out in a 
transgenic embryo and looking to see if dystrophy is still rescued. Once it is determined 
which domains are necessary it would be possible to look at the proteins that interact with 
those domains. With this knowledge, we could look downstream of the signaling 
pathways of those proteins to come up with a mechanism.  Thus, the purpose of this 
thesis is to investigate domains of Paxillin that play a critical role in ameliorating 
muscular dystrophy. 
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Materials and Methods 
 
Zebrafish Husbandry:  
 Zebrafish were set up for natural spawning in a facility that is kept on a 16-hour 
light/8-hour dark cycle. The zebrafish lines of interest that were used for this study were 
transgenic for overexpression of Paxillin. This process involves inserting a transgene 
(such as Paxillin with a domain knocked out) into the single celled embryonic stage. The 
transgene is intended to be inserted wherever there are transposable elements within the 
genome. However, it is not a perfect system and the transgene does not always get 
inserted. Furthermore, in order to be passed on to the next generation the transgene must 
be inserted into an autosome. It is not guaranteed that this process will be successful, thus 
it is necessary to cross male and female pairs and identify the embryos as carriers of the 
transgene. The inserted Paxillin transgene is tagged with green fluorescent protein (GFP), 
which fluoresces under a UV microscope. This is used to identify carriers.  
 Once a male and female pair has been identified as carriers of the transgene they 
are moved into a new tank. The offspring that also carry the transgene can then be reared 
and breed within a few months. The first part of this thesis was to identify the carriers of 
the transgene that would be used for further studies. Eggs from these identified parents 
were collected in the morning and kept in embryo rearing medium (ERM) in a 28 ̊ C 
incubator.  
Investigating Different Ethanol (EtOH) Dosages 
 Preliminary research was required to determine the dilution of EtOH that was 
sufficient for inducing fiber detachment in the embryos. Embryos were reared in different 
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solutions of varying dilutions of ERM:EtOH across two different lines of Paxillin 
transgenics: HS Paxillin GFP (green fluorescent protein) and β-actin Paxillin GFP. 
 The β-actin Paxillin embryos were divided into four groups: 0% EtOH, 1.5% 
EtOH, 1.75% EtOH, and 2% EtOH. To make each solution 200 proof EtOH stock 
solution was diluted in ERM. Embryos were reared in pure 1x ERM immediately 
following egg collection and were transferred to the EtOH solution at 24hpf (hours post 
fertilization). The EtOH solution was changed with fresh solution daily and dead 
embryos and empty chorions were removed. The embryos were fixed at 72hpf. All the 
embryos fluoresced positive for GFP, thus there were no wild type controls for this trial.  
 There was a much lower yield of HS Paxillin embryos than β-actin Paxillin, so it 
was only possible to use two groups. These were 1.75% EtOH heat-shocked embryos, 
and 1.75% EtOH non heat-shocked embryos. Heat-shocking is necessary to activate the 
overexpression of Paxillin. 24 hpf embryos were heat-shocked in an incubator at 42 ̊ C 
for one hour and 30 minutes. Since there was such a low yield of embryos there were no 
0% EtOH controls.  
Investigating the Necessity of the Paxillin LD2 Domain in Ameliorating Dystrophy: 
 The HS Paxillin (-LD2) GFP transgenics overexpress Paxillin with the LD2 
domain knocked out. They were divided into four groups: 0% EtOH heat shocked, 0% 
EtOH no heat-shock (controls), 2% EtOH heat-shocked, and 2% EtOH no heat-shock. To 
make each solution 200 proof EtOH stock solution was diluted in ERM. Embryos were 
reared in pure 1x ERM immediately following egg collection. The embryos were heat-
shocked at 42 ̊ C for one hour and 30 minutes, and then immediately transferred to the 
2% EtOH solution. The EtOH solution was changed daily and dead embryos and empty 
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chorions were removed. The embryos were fixed at 72hpf. Not all of the heat-shocked 
embryos fluoresced positive for GFP under a fluorescent light, thus some controls were 
also built into the trial.  
Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs: 
 Three lines of Paxillin transgenics were used for this trial: HS Paxillin GFP, HS 
Paxillin (-LD2) GFP, and HS Paxillin (-LD4) GFP. Each line was divided into two 
groups: 0% EtOH heat-shocked and 2% EtOH heat-shocked. The embryos were heat-
shocked at 42 ̊ C for one hour and 30 minutes, and then transferred to the 2% EtOH 
solution. This solution was made by diluting 200 proof EtOH stock solution in 1x ERM. 
The EtOH solution was changed daily and dead embryos and empty chorions were 
removed. The embryos were fixed at 72hpf.   
Immunofluorescent Staining: 
 The embryos are contained within a thin membrane called the chorion at 
fertilization, but most break out of this by 72hpf. The chorion was manually removed 
with forceps for those that had not, and the embryos were added to tubes in groups of 10-
15. This prevents the embryos from fixating in a curled position, and makes imaging 
much cleaner. The embryos were fixed in 4% paraformaldehyde (PFA) for four hours at 
room temperature on a rocker, or overnight at 4 ̊ C. This was followed by rinsing five 
times for five minutes each in PBS-0.1% Tween20 (PBS-Tw) on a rocker. The embryos 
were then permeabilized in PBS- 2% Triton (PBS-Tx) solution for one and a half hours 
on a rocker.  
 Immediately following permeabilization 20µL of 1:20 dilution of Phalloidin: 
Alexa fluor 546:PBS-Tw were added to each tube. The tubes were kept under foil from 
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this point forth since phalloidin degrades under light. The embryos were phalloidin 
stained either from 2-4 hours at room temperature on a rocker, or overnight at 4 ̊ C. They 
were then rinsed in PBS-Tw for five times for five minutes each.  
Imaging: 
 It is necessary to remove the yolk from the embryos and sever the head before 
attempting to image them as this will facilitate clear images by allowing the embryos to 
lie flat. The yolk was removed in 1% PBS with small dissecting pins. The embryos were 
then mounted on a slide in 20% PBS/80% glycerol. The embryos were imaged with a 
Zeiss Axio Imager Z1 microscope with a Zeiss ApoTome attachment. Images were taken 
at the 20x objective with five frame averaging.  
 Z-stack images were obtained at 0.55µm thick slices with several filters. A 
rhodamine filter was used to view the F-actin in the muscle cells that were phalloidin 
stained and depicted in red. The green staining is showing the GFP tag on Paxillin with 
the LD2 domain knocked out.  
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Results 
 
 In order to determine which domains of Paxillin are important to ameliorate 
dystrophy we need a zebrafish model of muscular dystrophy. Unfortunately, around the 
time I began this research, the standard Henry lab technique for generating zebrafish with 
muscular dystrophy stopped working (we used morpholinos and the company changed its 
purification methods rendering them more useful for cell culture experiments but more 
toxic in zebrafish). Thus, I needed a new way to generate dystrophy. I turned towards 
using EtOH exposure as a way to induce dystrophy in the zebrafish. Most of the current 
research on EtOH has been on pre-muscle development for the purpose of studying fetal 
alcohol syndrome. The Henry Lab has been interested in the effects of EtOH in post-
muscle development. Preliminary studies have shown that adding EtOH after 24hpf can 
induce dystrophy in wildtype zebrafish. This will be a useful technique for studying 
dystrophy since EtOH is both easy to use and readily available.  
 Dystrophy can then be measured by the number of embryos that display fiber 
detachments as well as the overall percent of myotomes that have fiber detachments in 
each embryo. These measurements would then be indicative of the ability of Paxillin to 
ameliorate dystrophy. Comparisons can be made between zebrafish with different 
domains knocked out as well as to zebrafish that are expressing the complete Paxillin 
sequence.  
Overview of Transgenics and Treatments:  
  We have multiple controls for these experiments. β-actin Paxillin zebrafish 
express Paxillin from a constitutive (always active) promoter. Alternatively, HS promoter 
allows us to control when during muscle development Paxillin is turned on by heat 
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shocking the embryos. However, we also need a group of zebrafish transgenic for HS 
Paxillin that are controls and are not heat shocked. We will refer to these as non-heat 
shocked Paxillins.  
Investigating Different EtOH Dosages:  
 Before we could begin to test the efficacy of Paxillin with different domains 
knocked out we had to determine what dose of EtOH would be sufficient to induce 
dystrophy. The β-actin Paxillin control group that was not treated with EtOH showed no 
adverse muscle development, as expected. The β-actins treated with 1.5% EtOH also had 
healthy muscle with no fiber detachments (fig 4). The 1.75% EtOH treated β-actins 
however had 17.6% occurrence of dystrophy across all embryos at n = 28. The HS 
Paxillin embryos that were heat-shocked and treated with the same 1.75 % EtOH dose 
only had a 3% occurrence of dystrophy at n = 32. This result was initially exciting, but 
then analyzing the other control group, the non-heat shocked Paxillins at 1.75% EtOH, 
showed normal muscle development with no fiber detachments. Thus, because the non-
heat shock Paxillin controls did not show dystrophy it is difficult to make any 
conclusions from this experiment. 
 The β-actin Paxillins that were treated with a 2% EtOH dilution also had a 17.6% 
occurrence of dystrophy across all embryos at n = 28 (fig 2). Embryos from this group 
that did not have fiber detachments displayed abnormally curvy muscle cells (fig 3). 
Although the β-actin Paxillins displayed more dystrophy with EtOH treatment than the 
HS Paxillins, the Henry Lab only has transgenics with different domains of Paxillin 
knocked out with the HS promoter. Since all of the subsequent studies would involve 
domain knock outs it was decided to use a 2% EtOH dilution for future studies since 
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1.75% EtOH treatment had too low of an occurrence of dystrophy in the HS Paxillins. 
Figure 4 shows a complete comparison.  
Investigating the Necessity of the Paxillin LD2 Domain in Ameliorating Dystrophy: 
 One of the domains of Paxillin that we predicted might play a role in rescuing 
dystrophy is the LD2 domain. I was interested in this domain because it has been 
recognized as acting as a docking site for focal adhesion kinase (FAK).[13] Thus, if 
Paxillin is unable to rescue dystrophy with the LD2 domain knocked out that would 
indicate that FAK may be involved downstream of the signaling pathway. Unfortunately, 
this experiment is also difficult to interpret because of contamination of the dishes. We 
have found that sometimes contamination can cause aberrant development that is not 
specific to the treatment/mutation we are trying to study. 
 At 24hpf all the petri dishes had contamination. Most were in the control dishes 
but some were in the EtOH treated dishes as well. This may affect the results. The non-
heat shocked HS Paxillin embryos with no EtOH treatment acted as the controls for this 
experiment. As expected, both the wild type and the fluorescing (signifying they are 
transgenic) embryos had no fiber detachments (fig 5) since they were not treated with 
EtOH. The heat shocked HS Paxillins had a 6% occurrence of dystrophy across all 
embryos at n = 18. This 6% is a bit misleading because it is all due to the fact that one 
embryo had fiber detachments on four myotomes (fig 6). ). This outlier could have 
occurred because the heat shock treatment done at 42 ̊ C for 1.5 hours, which could be 
too severe. One other reason could be that a number of the genes that promote muscle 
cell adhesion to laminin are maternally expressed.[11] Thus, if the mother does not happen 
to deposit enough RNA and proteins in the eggs they will be more likely to show 
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dystrophy. Some other unknown event may have resulted in dystrophy in this embryo as 
well, but regardless of the reason for the outlier, 17/18 embryos had normal muscle 
development.   
 The next part of this experiment was to heat shock the HS Paxillin (-LD2) 
embryos that have the LD2 domain knocked out and compare them to HS Paxillin 
embryos with full length Paxillin. The heat-shocked HS Paxillin (-LD2) GFP embryos 
that were treated with 2% EtOH and did not fluoresce, meaning they weren’t 
overexpressing Paxillin with the LD2 domain knocked-out, had a 52% occurrence of 
dystrophy across all embryos at n = 25 (fig 7). The average number of myotomes with 
fiber detachments was 3.76 myotomes (fig 8). This average was low since it takes into 
account all the embryos in the group that had no fiber detachments, however many of the 
affected embryos had extremely severe dystrophy with as many as 19 myotomes with 
dystrophy (fig 9). We do not understand the etiology of this variation, but some potential 
causes of this variability will be considered in the discussion. 
 The experimental embryos are those that express HS Paxillin (– LD2) and 
fluoresced, indicating that they are GFP positive and transgenic. If dystrophy is still 
rescued with the LD2 domain knocked out, then that domain is not necessary for 
amelioration of dystrophy. Unfortunately, in this experiment, there were only two 
embryos that fluoresced. The heat-shocked HS Paxillin (-LD2) GFP embryos that were 
treated with 2% EtOH and fluoresced had a 50% occurrence of dystrophy n = 2. The one 
embryo with fiber detachments shown in figure 10 (red showing F-actin and green 
showing GFP) had the same severity of dystrophy as the non-fluorescing group had. This 
embryo had 19 myotomes with fiber detachments.  
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Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs:  
 Another domain of Paxillin that we predicted might play a role in rescuing 
dystrophy is the LD4 domain. Fibroblasts that express the LD4 domain have been 
associated with poor focal adhesion, thus we predict that knocking out this domain may 
actually make Paxillin more efficient in ameliorating dystrophy. This domain is also a 
docking site for FAK, just like the LD2 domain, and has the potential for downstream 
signaling.[13] This experiment also retested 2% EtOH treatment on the HS Paxillin (-LD2) 
and HS Paxillin embryos. However, at 72hpf both the HS Paxillin (-LD4) and HS 
Paxillin (-LD2) embryos that were treated with 2% EtOH were dead. These embryos had 
been alive at 48hpf when the EtOH solution was changed. Since the breeding zebrafish 
with the Paxillin LD4 domain knock out were so young and still growing, we were 
unable to obtain another spawn from them. Thus, no further testing with the LD4 knock 
out was completed in this study.  
 The HS Paxillin embryos with 2% EtOH survived and were used for further 
analysis. The heat shocked HS Paxillin controls with no EtOH treatment had no fiber 
detachments at n = 10 embryos (fig 11). The heat shocked HS Paxillin embryos that were 
treated with 2% EtOH and fluoresced (were transgenics) had a 60% occurrence of 
dystrophy across all embryos at n = 10. Those that had fiber detachments appeared to be 
just as severe as the HS Paxillin (-LD2) embryos from the previous experiment (fig 12). 
A comparison of the occurrence of dystrophy for both groups is shown in figure 13. All 
of the EtOH treated embryos from each experiment had the majority of the fiber 
detachments occur nearer to the head region than the tail (fig 14). These embryos also 
exhibit very short and wide myotomes. The embryos from the EtOH treated HS Paxillin 
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embryos with the domain knock outs also appeared short and stumpy when viewed under 
a dissecting microscope. Control embryos did not express this phenotype, implicating this 
happening in response to the EtOH treatment. Potential reasons for these differences will 
be discussed further in the discussion.  
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Discussion 
 
 The results from this these experiments are not conclusive since every experiment 
had something go wrong – not enough controls, not enough experimental embryos, 
contamination, etc. However, these experiments do give insight into the dilution of EtOH 
that is sufficient to induce dystrophy as well as allude to some interesting differences 
between the different Paxillin transgenic lines.  
Investigating Different EtOH Dosages:  
 There was a difference of 14.6% in the responses of the β-actin Paxillins and the 
HS Paxillins to 1.5% EtOH. This discrepancy across the lines makes studying the ability 
of overexpression of Paxillin difficult using EtOH. More surprisingly, the non-heat 
shocked HS Paxillins at 1.5% EtOH having seemingly healthy muscle suggests an 
inconsistency with the EtOH treatment since this was the same dose on the same line. 
This could be due to the heat shock process facilitating fiber detachment by stressing the 
muscle. The Henry Lab recently determined that the temperature of 42 ̊ C may be much 
higher than the level the embryos can withstand before muscle formation is affected. A 
shorter exposure time or a lower temperature may be required to avoid malformations.  
Investigating the Necessity of the LD2 Domain in Ameliorating Dystrophy: 
 The heat-shocked HS Paxillin (-LD2) GFP embryos that were treated with 2% 
EtOH that both fluorescing and non-fluorescing (were not transgenic) showed extreme 
dystrophy. Not only did they have an unusually high amount of fiber detachments, but 
most of the dystrophy was seen anteriorly more frequently than posteriorly. Under 
normal circumstances fiber detachments are more numerous in the tail region around 
myotomes 10-15. These embryos with 2% EtOH treatment had fiber detachments 
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occurring more frequently in the anterior region around myotomes 5-10. This could be 
occurring in response to the age of the muscle cells. Zebrafish embryos develop in a head 
to tail fashion, thus the muscle cells in the tail are much younger than the muscle cells 
near the head. Perhaps the older muscle cells are more sensitive to the EtOH treatment 
than the younger ones.  
 The contamination of the dishes must also be regarded when trying to determine 
the cause of the unusually severe dystrophy. The Henry Lab has observed that 
contamination in the dishes generally results in curled embryos after hatching from the 
chorion. In most cases motility is negatively affected. The control groups for this 
experiment, heat shocked 0% EtOH and non-heat shocked 0% EtOH, had straight, 
healthy looking bodies before fixing at 72hpf. Some of the EtOH treated embryos had 
curled or stumpy bodies, but this has also been observed with EtOH treatment when there 
was no contamination present. However, the EtOH treatment may contribute to the 
contaminating microorganisms thriving better than in ERM solution alone and result in 
severe dystrophy. This is only conjecture and cannot be validated without further testing.  
 Only two embryos fluorsced (were transgenic) which is too small of a sample to 
be able to glean any information from. Furthermore, although the transgenic HS Paxillin 
(-LD2) did not rescue dystrophy this cannot be linked to a lack of an LD2 domain since 
the full length HS Paxillin embryos also could not rescue dystrophy with EtOH treatment. 
Thus, domain knock outs cannot be studied using EtOH treatment as a means to induce 
dystrophy. This is more evident from the results of the next section.  
Investigating Paxillin Overexpression with LD2 or LD4 Domain Knock-outs:  
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 It was very unfortunate that all of the HS Paxillin embryos with the LD2 and LD4 
domains knocked out died since a comparison of the two had the potential to yield 
interesting results. However, since the HS Paxillins that survived and had full length 
Paxillin had a 60% occurrence of dystrophy for 10 embryos, it is evident that Paxillin is 
unable to rescue dystrophy at all that is caused by EtOH. Thus, different methods will 
have to be implemented in future studies to study the different domains of Paxillin and 
amelioration of dystrophy.  
 Here I will hypothesize some of the reasons behind the trends we observed (if one 
temporarily ignores the caveats of the experiments). The major issue with using EtOH 
treatment was that it was extremely inconsistent. A dose that was sufficient to induce 
phenotypic symptoms of muscular dystrophy in one experiment would annihilate whole 
dishes of embryos when it was used for another. This suggests that EtOH is overall toxic 
to the zebrafish embryos. Because of this, there is a limit to the amount of EtOH they can 
withstand, but the sensitivity to EtOH may vary depending on the clutch.  
 One possible reason for this variation in response to the treatment may be timing 
of hatching from the chorion. The chorion is a thin membrane that envelops and protects 
developing embryos until about 48-72hpf when they hatch.[12] The embryos that perished 
in the HS Paxillin experiments with 2% EtOH were alive at 48hpf and dead when 
checked at 72hpf. It is possible that the chorion is non-permeable or semipermeable to 
EtOH, thus the embryos were exposed to greater concentrations of EtOH after hatching. 
Since there is a lot of variability in the timing of hatching, this may have resulted in the 
variability of the effects of EtOH. The embryos that hatched later may have had a shorter 
exposure time to EtOH and had severe dystrophy, such as the heat shocked HS Paxillin (-
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LD2) GFP embryo seen in figure 9. Alternatively, the embryos that hatched earlier would 
have had a longer exposure time to EtOH and died from the toxicity. This is only a 
hypothesis and would require further testing.  
 There is also potentially a difference in the sensitivity of the different lines of 
Paxillin transgenics. In the last experiment that was conducted, the HS Paxillin (-LD2) 
and the HS Paxillin (-LD4) embryos died while the HS Paxillin embryos survived. This 
may suggest that the embryos are more sensitive to EtOH treatments when the LD2 and 
LD4 domains are knocked out. However, I was identifying transgenic embryos by 
looking for fluorescing MTJs after they were fixed during the imaging process, so it is 
not certain whether all the embryos in those dishes were transgenic since they died and 
degraded before they could be imaged.  
 There is also the issue that Paxillin was unable to rescue dystrophic embryos in 
these experiments. Previous studies that used overexpression of Paxillin to ameliorate 
dystrophy used morpholinos that targeted dystroglycan to induce dystrophy.[9] Since 
EtOH treated fish could not be rescued with Paxillin overexpression, it appears it is 
working via some other pathway. Additional evidence of this is seen in the body shape of 
the embryos that perished and in some of those that survived EtOH treatment. These 
embryos had very short, stumpy bodies with wide myotomes (fig 12). These embryos 
look very similar to laminin mutants that are missing laminin-111.  
  If EtOH is affecting laminin and not dystroglycan (which we previously targeted 
with MOs) this may explain why Paxillin cannot help ameliorate dystrophy. Previous 
studies associated overexpression of Paxillin with an increased polymerization of laminin 
at the MTJ, which improved cell anchorage to the basement membrane.[9] If EtOH 
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directly or indirectly disrupts laminin to a greater extent, then Paxillin overexpression 
might not be sufficient to ameliorate dystrophy. However, there are some inconsistencies 
in that not all embryos displayed the same stumpy tail phenotype. It was, like all other 
aspects of EtOH treatment, varied per each trial. The HS Paxillin (-LD2) embryos and the 
HS Paxillin embryos from the EtOH dosage experiment did not display this phenotype 
(fig 9).   
 We cannot make any conclusive hypotheses about the LD domains of Paxillin 
because the EtOH treatment was so unreliable. However, the results do give some 
inclinations about the potential sensitivity of these domains that we can keep in mind 
going forward with a different approach. These experiments have also given rise to some 
new hypotheses about EtOH treatment that could guide further studies.  
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Figures 
 
 
 
 
Figure 1. 72hpf β -actin Paxillin treated with a 1.75% dilution of EtOH. Fiber detachments 
are present. This embryo also has damage to the muscle cells that was inflicted during the 
deyolking process.  
 
 
 
 
 
Fig 2. 72hpf β -actin Paxillin treated with 2% EtOH. Muscle cells appear wavy and fiber 
detachments are present. 
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Figure 3. 72hpf β –actin Paxillin treated with 2% EtOH. Although there are no visible fiber 
detachments, the muscle cells appear wavy.  
 
 
 
 
 
 
Figure 4. Graph of the percent of HS Paxillin and β-actin Paxillin embryos with dystrophy 
at 72hpf. This was merely preliminary data that was lacking controls, however it does suggest an 
inconsistency with EtOH treatment both across different Paxillin transgenics lines as well as 
within the same lines at the same dose. 
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Figure 5. 72hpf Non-heat shocked Paxillin embryo 0% EtOH, myotome 10. There are no 
fiber detachments and the muscle cells appear straight and uniform.  
 
 
 
 
 
 
Figure 6. Heat-shocked HS Paxillin 0% EtOH, myotome 5. There are a large amount of fiber 
detachments on four myotomes.  
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Figure 7. Graph of the percent of HS Paxillin (-LD2) GFP embryos with dystrophy at 
72hpf. This graph takes into consideration the average percent of dystrophy across all embryos in 
each group. There was one outlier in the HS Paxillin 0% EtOH group that had dystrophy, 
resulting in a 6% average that misrepresents the group.  
 
 
 
 
 
Figure 8. Graph of the average number of myotomes with dystrophy for HS Paxillin (-LD2) 
embryos at 72hpf. This graph takes into account the average number of myotomes all of the 
embryos in each group had. The HS Paxillin 2% EtOH that fluoresced is misleading because 
there were only two embryos (one with dystrophy on 19 myotomes and one with no dystrophy). 
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Figure 9. 72hpf heat shocked HS Paxillin (-LD2) GFP non-fluorescing embryo with 2% 
EtOH treatment. The image starts at myotome five. The dystrophy is so severe that is nearly 
impossible to see myotome boundaries.  
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Figure 10. 72hpf heat shocked HS Paxillin (-LD2) GFP fluorescing embryo with 2% EtOH 
treatment. The image stars at myotome five. In image A The red staining depicts F-actin and the 
green depicts GFP. The embryo was curled, so the image cuts off at the top. Image B is the 
phalloidin stain in grey scale. There are severe muscle detachments.  
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Figure 11. 72hpf heat shocked HS Paxillin control with no EtOH treatment, myotome 10. 
Muscle development appears healthy and there is no evidence of fiber detachments.  
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Figure 12. 72hpf heat shocked HS Paxillin fluorescing (transgenic) embryo with 2% EtOH 
treatment, myotome 8. Image A shows GFP (demonstrating the embryo is a transgenic) in green 
and F-actin in Red. Image B shows only the red phalloidin staining for F-actin so fiber 
detachments are more visible.  
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Figure 13. Graph of the percent of 72hpf HS Paxillin embryos with dystrophy n = 10. 60% 
of the group that was treated with 2% EtOH had fiber detachments. None of the embryos that 
were not treated with EtOH had fiber detachments.  
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Figure 14. 72hpf heat shocked HS Paxillin fluorescing (transgenic) embryo with 2% EtOH 
treatment, myotome 15. Image A shows GFP (demonstrating the embryo is a transgenic) in 
green and F-actin in Red. Image B shows only the red phalloidin staining for F-actin so fiber 
detachments are more visible. This is the same embryo from figure 14 imaged in the tail region to 
demonstrate that fiber detachments occur more frequently anteriorly than posteriorly with EtOH 
treatment.  
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Appendix 
All procedures involving zebrafish (Danio rerio) described here are reviewed and 
approved by the IACUC at the University of Maine 
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